Search

Your search keyword '"Illert, Anna L"' showing total 167 results

Search Constraints

Start Over You searched for: Author "Illert, Anna L" Remove constraint Author: "Illert, Anna L"
167 results on '"Illert, Anna L"'

Search Results

2. Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors

3. Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform

5. Gene editing of hematopoietic stem cells restores T-cell response in familial hemophagocytic lymphohistiocytosis

6. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation

9. Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity

10. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

11. Primary results of patients with genitourinary malignancies presented at a Molecular Tumor Board

14. CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges

15. Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model

17. Community-driven development of a modified progression-free survival ratio for precision oncology

18. MIRACUM-Pipe: An Adaptable Pipeline for Next-Generation Sequencing Analysis, Reporting, and Visualization for Clinical Decision Making

19. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer

20. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

21. Abstract 926: Genomics-based personalized oncology of advanced thymic epithelial tumors

22. Data from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

23. Supplementary Tables S1-S7 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

24. Supplementary Figures S1-S10 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

25. Supplementary Methods from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

26. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

27. Profile of the Multicenter Cohort of the German Cancer Consortium’s Clinical Communication Platform

28. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation

29. Bcl‐x Las prognostic marker and potential therapeutic target in cholangiocarcinoma

30. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany

31. Gene expression-based prediction of pazopanib efficacy in sarcoma

33. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy (vol 135, pg 1, 2020)

34. Corrigendum to “Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’” [European Journal of Cancer 135 (2020) 1-7]

35. Corrigendum to 'Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group Molecular Diagnostics and Therapy'

37. The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML

38. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

39. Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis

40. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'

41. Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management

42. Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management

43. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’

44. A novel conditional NPM-ALK-driven model of CD30+ T-cell lymphoma mediated by a translational stop cassette

45. Erratum : Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

46. Corrigendum: Mycobacteria exploit nitric oxide-induced transformation of macrophages into permissive giant cells

48. Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia

49. Mycobacteria exploit nitric oxide‐induced transformation of macrophages into permissive giant cells

50. Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Catalog

Books, media, physical & digital resources